Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Institution	Shares	Value	Change
BlackRock	6,044,633	$57M	INCREASED
State Street	2,319,906	$22M	INCREASED
Badgley Phelps Wealth Managers	263,556	$3M	UNCHANGED
BNY Mellon	195,990	$2M	INCREASED
Mml Investors Services	118,175	$1M	INCREASED

Omeros Corporation (OMER) Ownership & Trading Activity

Top Institutional Holders